Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, sold 10,000 shares of Common Stock on June 16, 2026 in two open-market transactions under a Rule 10b5-1 trading plan adopted on March 12, 2026. The shares were sold at weighted average prices of $83.5708 and $82.6948 per share, with actual prices ranging from $82.13 to $83.935 per share. Following these sales, the trust continues to hold more than 1.09 million shares according to the filing, while two separate 2025 Grantor Retained Annuity Trusts each report indirect holdings of 200,000 shares. Wilson disclaims beneficial ownership of the trust shares except to the extent of his pecuniary interest.
Corcept Therapeutics director David L. Mahoney reported an indirect open-market sale of common stock through The Black Dog Private Foundation. The foundation sold 20,000 shares at a weighted average price of $84.5253 per share, with individual prices ranging from $84.44 to $85.11.
After the sale, the foundation held 26,147 shares of Corcept common stock. A separate indirect holding, the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust, is shown with 1,237,145 shares of common stock following the reported transactions.
Corcept Therapeutics has resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushing’s syndrome. The resubmission includes additional analyses of data from prior studies, as requested by the FDA, and is expected to receive a six-month review.
The filing highlights positive results from Corcept’s GRACE and Phase III GRADIENT trials, a long-term extension study and earlier-stage data, which the company believes show meaningful, durable improvements in Cushing’s symptoms without some serious side effects seen with existing therapies. Relacorilant already holds orphan drug designations and is approved as Lifyorli for platinum-resistant ovarian cancer.
Corcept Therapeutics’ Chief Financial Officer Atabak Mokari reported option exercises and related share sales in the company’s common stock. He exercised stock options covering 40,000 shares at an exercise price of $19.26 per share, then sold 40,000 shares in multiple open-market transactions at weighted average prices between approximately $79.40 and $82.18 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 16,130 common shares, which include shares underlying several unvested restricted stock awards scheduled to vest on their one-year anniversaries if service conditions are met.
The Charles Schwab Corporation provided a Form 144 notice related to proposed transactions in Common stock. The filing lists 20,000, 1,666,800.00, and 107,351,594 as numeric entries and references 06/16/2026 and NASDAQ.
Corcept Therapeutics’ Chief Development Officer William Guyer reported an exercise-and-sell transaction in company stock. He exercised options to acquire 20,000 shares of common stock at a price of $21.65 per share, then sold 20,000 shares at a weighted average price of $70.60 per share in an open-market transaction.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024. Following these transactions, he directly holds 3,985 shares of common stock and stock options for 150,000 shares that are fully exercisable, along with additional unvested restricted stock awards scheduled to vest one year after their respective grant dates.
Corcept Therapeutics officer Joseph Douglas Lyon reported routine equity compensation and related tax withholding transactions. On June 1, 2026, he acquired 537 shares of common stock at $0.00 per share as a grant or award, and a separate 537-share acquisition was priced at $70.44 per share under a purchase plan tied to the closing price that day. On June 2, 2026, 269 shares were withheld by Corcept at $70.44 per share to satisfy tax obligations on vesting restricted stock units. After these transactions, he directly held 7,035 common shares, including unvested restricted stock that will vest on one-year anniversaries of their grant dates if conditions are met.
Corcept Therapeutics Chief Development Officer William Guyer reported stock-based compensation and share purchases in company stock. On June 1, 2026, he acquired 877 shares of common stock as a grant at $0.00 per share and an additional 877 shares at $70.44 per share under a purchase plan established within the 2024 Incentive Award Plan. Footnotes show these include shares underlying unvested restricted stock awards, which vest in full one year after their grant dates if service and ownership conditions are met.
Corcept Therapeutics (CORT) officer Sean Maduck reported a series of equity transactions involving company common stock. He exercised stock options for 25,000 shares at $8.27 per share and on the same date sold 25,000 shares in open-market transactions at weighted average prices of about $70–71 per share under a pre-arranged Rule 10b5-1 trading plan. The company also withheld 452 shares valued at $70.44 per share to cover tax obligations on vesting of restricted stock units, which is not an open-market sale. Following these transactions, Maduck holds 9,755 shares directly, plus indirect interests including 10,000 shares in a living trust, 34,000 in MMM 2025, LLC, 40,000 and 20,570 shares in two Grantor Retained Annuity Trusts, and 5,147 shares in Duckhill Capital, LLC, where he disclaims beneficial ownership beyond his pecuniary interest.